Choksi Asia Ltd (CHOKSI) — shareholding pattern, promoter holding, financials and share price
About Choksi Asia Ltd (CHOKSI)
Choksi Asia Ltd operates in the Medical Equipment & Supplies industry, within the Healthcare sector. It trades on the NSE as CHOKSI and on the BSE under scrip code 530427. Its ISIN is INE865B01016.
Incorporated in 1992, Choksi Imaging Ltd manufactures and trades X-ray films that find application in medical imaging. In addition, it is engaged in the trading of various items used in the healthcare industry.
Choksi Imaging Ltd, originating as Selvas Photographics Ltd, was established in 1992 and is led by the third generation of the Choksi family. It specializes in manufacturing photosensitized materials for the photographic and medical industries.
Its primary products include x-ray films used extensively by radiologists and industrial radiographers. The company experienced a significant boost in turnover by 41.75% in 2000-01 due to the sale of photographic color paper.
Listed peers in Medical Equipment & Supplies: Avience Biomedicals Ltd, Aakaar Medical Technologies Ltd, Royal Sense Ltd, Shree Pacetronix Ltd, KMS Medisurgi Ltd, Amkay Products Ltd.
Valuation & Returns
10 Jul 2026At ₹173 a share on 10 Jul 2026, Choksi Asia Ltd (CHOKSI) was valued at a price-to-earnings ratio of 18.61x against an industry P/E of 44.11x and a price-to-book of 3.13x on a book value of ₹55.24 per share as of Mar 2025. Solomo computes return on equity of 16.83% and return on capital employed of 19.02% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 18.61x
- Industry P/E
- 44.11x
- P/B
- 3.13x
- EPS (TTM)
- ₹9.3
- Book value / share
- ₹55.24
- ROE
- 16.83%
- ROCE
- 19.02%
- ROA
- 11.23%
- Debt / equity
- 0.32x
- Dividend yield
- 0%
- EBITDA margin
- 16.61%
- 52-week range
- ₹75 – ₹212.9
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Choksi Asia Ltd (CHOKSI) reported revenue of ₹49.31 crore, net profit of ₹5.33 crore and earnings per share of ₹9.35. That compares with revenue of ₹36.98 crore and net profit of ₹3.1 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹11.86 crore and net profit ₹0.75 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 2.46 | 0.77 | 15.99 | 36.98 | 49.31 |
| Net profit (₹ cr) | -0.42 | -0.48 | 1.39 | 3.1 | 5.33 |
| EPS (₹) | -1.08 | -1.23 | 3.56 | 7.95 | 9.35 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | -3.50% | 18.24% | 146.66% | 131.27% |
| Profit growth | 4.05% | - | - | 123.02% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 71.15% of Choksi Asia Ltd (CHOKSI) (unchanged from the previous quarter), foreign institutional investors (FII) hold 0.18%. Market capitalisation was ₹99 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: YAMINI CHOKSI 3.01%, INVESTOR EDUCATION AND PROTECTION FUND A 1.48%, KASHMIRA MANISH MEHTA 1.38%, HUF 1.24%, BOSCO ARMANDO MENEZES 1.12%, EMILY BOSCO MENEZES 1.12%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 71.15% | - | 0.18% | - | 28.85% |
| Mar 2026 | 71.15% | - | - | - | 28.85% |
| Dec 2025 | 71.15% | - | - | - | 28.85% |
| Sep 2025 | 71.15% | - | - | - | 28.85% |
| Jun 2025 | 62.23% | - | - | - | 37.77% |
| Mar 2025 | 62.23% | - | - | - | 37.77% |
| Dec 2024 | 62.23% | - | - | - | 37.77% |
| Sep 2024 | 62.23% | - | - | - | 37.77% |